The cholinesterase inhibitor physostigmine for the local treatment of dry mouth: A randomized study

European Journal of Oral Sciences

Volumn 117, Issue 3, 2009, Pages 209-217

  Khosravani, Nina ^a   Birkhed, Dowen ^a   Ekström, Jörgen ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Dry mouth; Local application; Physostigmine; Salivation

Indexed keywords

CHOLINESTERASE INHIBITOR; PHYSOSTIGMINE; PLACEBO;

ADULT; AGED; ARTICLE; CHEMICALLY INDUCED DISORDER; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; GASTROINTESTINAL DISEASE; GEL; HUMAN; LIP; MALE; MIDDLE AGED; MOUTH MUCOSA; RANDOMIZED CONTROLLED TRIAL; SAFETY; SALIVA; SALIVATION; SECRETION; TIME; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME; XEROSTOMIA;

ADMINISTRATION, TOPICAL; ADULT; AGED; CHOLINESTERASE INHIBITORS; CROSS-OVER STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; GASTROINTESTINAL DISEASES; GELS; HUMANS; LIP; MALE; MIDDLE AGED; MOUTH MUCOSA; PHYSOSTIGMINE; PLACEBOS; SAFETY; SALIVA; SALIVATION; TIME FACTORS; TREATMENT OUTCOME; XEROSTOMIA; YOUNG ADULT;

EID: 65149100545     PISSN: 09098836     EISSN: 16000722     Source Type: Journal    
DOI: 10.1111/j.1600-0722.2009.00632.x     Document Type: Article

References (41)

1. Ship JA, Pillemer SR, Baum BJ. Xerostomia and the geriatric patient. J Am Geriatr Soc 2002 50 : 535 543. (Pubitemid 34229412)
2. Wärnberg Gerdin E, Einarson S, Jonsson M, Aronsson K, Johansson I. Impact of dry mouth on oral health-related quality of life in older people. Gerodontology 2005 22 : 219 226.
3. Goldie MP. Xerostomia and quality of life. Int J Dent Hyg 2007 5 : 60 61.
4. Österberg T, Landahl S, Hedegård B. Salivary flow, saliva pH and buffering capacity in 70-yr-old men and women. Correlation to dental health, dryness in the mouth, disease and drug treatment. J Oral Rehab 1984 11 : 157 170.
5. Nederfors T, Isaksson R, Mörnstad H, Dahlöf C. Prevalence of perceived symptoms of dry mouth in an adult Swedish population - relation to age, sex and pharmacotherapy. Community Dent Oral Epidemiol 1997 25 : 211 216. (Pubitemid 127534004)
6. Wiseman LR, Faulds D. Oral pilocarpine: a review of its pharmacological properties and clinical potential in xerostomia. Drugs 1995 49 : 143 155.
7. Ekström J, Helander HF. Secretion from submucosal salivary glands of the ferret in response to a cholinesterase inhibitor applied onto the oral mucosa. Eur J Oral Sci 2002 110 : 230 236.
8. Khosravani N, Ekman R, Ekström J. Acetylcholine synthesis, muscarinic receptor subtypes, neuropeptides and secretion of ferret salivary glands with special reference to the zygomatic gland. Arch Oral Biol 2007 52 : 417 426. (Pubitemid 46420315)
9. Sreebny LM, Broich G. Xerostomia (dry mouth). In : Sreebny LM, ed. The salivary system. Boca Raton, FL : CRC Press, 1988 179 202.
10. Rossini RB, Machado AB, Machado CR. A histochemical study of catecholamines and cholinesterases in the autonomic nerves of the human minor salivary glands. Histochem J 1979 11 : 661 668. (Pubitemid 10169430)
11. Konttinen YT, Hukkanen M, Kemppinen P, Segerberg M, Sorsa T, Malmström M, Rose S, Itescu S, Polak JM. Peptide-containing nerves in labial salivary glands in Sjögren's syndrome. Arthritis Rheum 1992 35 : 815 820.
12. Izutsu K, Ensign W, Ramsey B, Schubert M, Allan B, Truelove E. Autonomic regulation of potassium release from human labial salivary glands in vitro. Arch Oral Biol 1988 33 : 519 523.
13. Turner RJ, Paulais M, Valdez II, Evans RL, Fox PC. Ion transport and signalling in human labial glands. Arch Oral Biol 1999 44 : S15 S19. (Pubitemid 29292935)
14. Riva A, Puxeddu R, Loy F, Testa Riva F. Morphofunctional studies on human labial salivary glands. Eur J Morphol 2002 40 : 227 233. (Pubitemid 37421793)
15. Hedner E, Birkhed D, Hedner J, Ekström J, Helander HF. Stimulation of minor salivary glands by intraoral treatment with the cholinesterase inhibitor physostigmine in man. Eur J Oral Sci 2001 109 : 371 374. (Pubitemid 33773332)
16. Khosravani N, Ekström J, Birkhed D. Intraoral stimulation of salivary secretion with the cholinesterase inhibitor physostigmine as a mouthspray: a pilot study in healthy volunteers. Arch Oral Biol 2007 52 : 1097 1101. (Pubitemid 47503121)
17. Pai S, Ghezzi EM, Ship JA. Development of a visual analogue scale questionnaire for subjective assessment of salivary dysfunction. Oral Surg Oral Med Oral Pathol Radiol Endod 2001 91 : 311 316. (Pubitemid 33608850)
18. Sern S. Cross-over trials in clinical research, 2nd edn. Hoboken, NJ : Wiley, 2002 205 243.
19. Heintze U, Birkhed D, Björn H. Secretion rate and buffer effect of resting and stimulated whole saliva as a function of age and sex. Swed Dent J 1983 7 : 227 238.
20. Grišius MM, Fox PC. Salivary gland dysfunction and xerostomia. In : Linden RWA, ed. The scientific basis of eating. Vol. 9. Front Oral Biol Basel : Karger, 1988 156 167.
21. Longman LP, Higham SM, Rai K, Edgar WM, Field EA. Salivary gland hypofunction in elderly patients attending a xerostomia clinic. Gerodontology 1995 12 : 67 72.
22. Field EA, Longman LP, Bucknall R, Kaye SB, Higham SM, Edgar WM. The establishment of a xerostomia clinic: a prospective study. Br J Oral Maxillofac Surg 1997 35 : 96 103. (Pubitemid 27182639)
23. Fox PC, Busch KA, Baum BJ. Subjective reports of xerostomia and objective measures of salivary gland performance. J Am Dental Assoc 1987 115 : 581 584.
24. Thomson WM, Chalmers JM, Spencer AJ, Ketabi M. The occurrence of xerostomia and salivary gland hypofunction in a population-based sample of older South Australians. Spec Care Dentist 1999 1 : 20 23.
25. Dawes C. Physiological factors affecting salivary flow rate, oral sugar clearance and the sensation of dry mouth in man. J Dent Res 1987 66 : 648 653.
26. Nordberg A, Svensson A-L. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology. Drug Saf 1998 19 : 465 480. (Pubitemid 29015406)
27. Asthana S, Greig NH, Hegedus L, Holloway HH, Raffaele KC, Schapiro MB, Soncrant TT. Clinical pharmacokinetics of physostigmine in patients with Alzheimer's disease. Clin Pharmacol Ther 1995 58 : 299 309.
28. Sharpless NS, Thal LJ. Plasma physostigmine concentrations after oral administration. Lancet 1985 1 : 1397 1398. (Pubitemid 15060942)
29. Thal LJ, Masur DM, Sharpless NS, Fuld PA, Davies P. Acute and chronic effects of oral physostigmine and lecithin in Alzheimer's disease. Prog Neuropsychopharmacol Biol Psychiatry 1986 10 : 627 636. (Pubitemid 17172648)
30. Hartwig P, Wiklund L, Aquilonius SM, Lindström B. Clinical pharmacokinetics of acetylcholinesterase inhibitors. In : Aquilonius SM, Gillberg PG, eds. Progress in brain research. Vol. 84. Amsterdam : Elsevier, 1990 193 194. (Pubitemid 20372993)
31. Wynn LR, Meiller TF, Grossley HL. Drug information handbook for dentistry. Lexi-Comp's Dental Reference Library™, 9th edn. Hudson, OH, USA : Lexi-Comp, 2004.
32. Taweechaisupapong S, Pesee M, Aromdee C, Laopaiboon M, Khunkitti W. Efficacy of pilocarpine lozenge for post-radiation xerostomia in patients with head and neck cancer. Aust Dent J 2006 51 : 333 337.
33. Gibson J, Halliday JA, Ewert K, Robertson S. A controlled release of pilocarpine buccal insert in the treatment of Sjögren's syndrome. Br Dent J 2007 202 : E17.
34. Speirs RL. Secretion of saliva by human lip mucous glands and parotid glands in response to gustatory stimuli and chewing. Arch Oral Biol 1984 29 : 945 948.
35. Hector MP, Linden RWA. Reflexes of salivary secretion. In : Garrett JR, Ekström J, Anderson LC, eds. Neural mechanisms of salivary glands. Vol. 11. Front Oral Biol Basel : Karger, 1999 166 184.
36. Johnson JT, Ferreti GA, Nethery WJ, Valdez IH, Fox PC, Ng D, Muscoplat CC, Gallacher SC. Oral pilocarpine for post-irradiation xerostomia in patients with head and neck cancer. N Engl J Med 1993 329 : 390 395. (Pubitemid 23219343)
37. Vivino FB, Al-Hashimi I, Khan Z, Leveque FG, Salisbury PL III., Tran-Johnson TK, Muscoplat CC, Trivedi M, Goldlust B, Gallacher SC. Pilocarpine tablets for the treatment of dry mouth and dry eye symptoms in patients with Sjögren syndrome. Arch Intern Med 1999 159 : 174 181.
38. Sano M, Bell K, Marder K, Stricks L, Stern Y, Mayeux R. Safety and efficacy of oral physostigmine in the treatment of Alzheimer disease. Clin Neuropharmacol 1993 16 : 61 69. (Pubitemid 23028499)
39. Thal LJ, Schwartz G, Sano M, Weiner M, Knopman D, Harrell L, Bodenheimer S, Rossor M, Philpot M, Schor J, Goldberg A. A multicenter double-blind study of controlled-release physostigmine for the treatment of symptoms secondary to Alzheimer's disease. Neurology 1996 47 : 1389 1395. (Pubitemid 26422525)
40. Van Dyck CH, Newhouse P, Falk WE, Mattes JA. Extended-release physostigmine in Alzheimer disease: a multicenter, double-blind, 12-week study with dose enrichment. Physostigmine study group. Arch Gen Psychiatry 2000 57 : 157 164. (Pubitemid 30075267)
41. Taylor P. Anticholinesterase agent. In : Hardman JG, Goodman Gilman A, Limbird LE, eds. Goodman and Gilman′s the pharmacological basis of therapeutics, 9th edn. New York : The McGraw-Hill Companies, 1995 161 176.